A5047999591- Congenital Heart Disease Studies
- Cardiac Valve Diseases and Treatments
- Aortic Disease and Treatment Approaches
- Pulmonary Hypertension Research and Treatments
- Cardiac Structural Anomalies and Repair
- Cardiovascular and Diving-Related Complications
- Mechanical Circulatory Support Devices
- Cardiac Arrhythmias and Treatments
- Infective Endocarditis Diagnosis and Management
- Coronary Artery Anomalies
- Cardiovascular Conditions and Treatments
- Cardiac pacing and defibrillation studies
- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Transplantation: Methods and Outcomes
- Vascular anomalies and interventions
- Cardiovascular Issues in Pregnancy
- Tracheal and airway disorders
- Cardiac Arrest and Resuscitation
- Glioma Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Renal and Vascular Pathologies
- Cardiovascular Function and Risk Factors
- Traumatic Brain Injury and Neurovascular Disturbances
- Vascular Anomalies and Treatments
University of Washington
2014-2024
Seattle Children's Hospital
2015-2024
Cedars-Sinai Medical Center
2015-2023
Sinai Hospital
2023
University of Washington Medical Center
2002-2022
Morgan Stanley Children's Hospital
2010-2017
Seattle University
1998-2017
Children's Hospital of Philadelphia
2012-2017
Columbia University
2007-2017
Children's Healthcare of Atlanta
2017
Background— Transcatheter pulmonary valve placement is an emerging therapy for regurgitation and right ventricular outflow tract obstruction in selected patients. The Melody was recently approved the United States dysfunctional conduits. Methods Results— From January 2007 to August 2009, 136 patients (median age, 19 years) underwent catheterization intended implantation at 5 centers. Implantation attempted 124 patients; other 12, transcatheter not because of risk coronary artery compression...
Background— Studies of transcatheter pulmonary valve (TPV) replacement with the Melody have demonstrated good short-term outcomes, but there are no published long-term follow-up data. Methods and Results— The US Investigational Device Exemption trial prospectively enrolled 171 pediatric adult patients (median age, 19 years) right ventricular outflow tract conduit obstruction or regurgitation. 148 who received were discharged a TPV followed up annually according to standardized protocol....
Background— Among patients undergoing transcatheter pulmonary valve (TPV) replacement with the Melody valve, risk factors for stent fracture (MSF) and right ventricular outflow tract (RVOT) reintervention have not been well defined. Methods Results— From January 2007 to 2010, 150 (median age, 19 years) underwent TPV implantation in Investigational Device Exemption trial. Existing conduit stents from a prior catheterization were present 37 (25%, fractured 12); 1 or more new prestents placed...
Background— The Melody transcatheter pulmonary valve (TPV) was approved for implantation in obstructed right ventricular outflow tract conduits 2010 after a multicenter trial demonstrating improvements conduit obstruction, regurgitation, and pressure. A recognized risk contraindication to TPV is the demonstration of coronary artery (CA) compression during balloon angioplasty or stent placement overlying conduit. This study first characterize CA this population. Methods Results— From 2007...
Background— Off-label use of transcatheter aortic and pulmonary valve prostheses for tricuspid valve-in-valve implantation (TVIV) within dysfunctional surgical (TV) bioprostheses has been described in small reports. Methods Results— An international, multicenter registry was developed to collect data on TVIV cases. Patient-related factors, procedural details outcomes, follow-up were analyzed. Valve-in-ring or heterotopic TV procedures not included. Data collected 156 patients with...
Abstract Objectives Characterize the safety and effectiveness of Amplatzer Piccolo Occluder for patent ductus arteriosus (PDA) closure. Background The presence a hemodynamically significant PDA has been associated with an increased risk morbidity mortality in children born premature. Methods This was single arm, prospective, multicenter, non‐randomized study to evaluate treat patients ≥700 g. From June 2017 February 2019, 200 were enrolled at nine centers, 100 weighing ≤2 kg. Primary...
Abstract Background: We report a multi‐institutional experience with intravascular stenting (IS) for treatment of coarctation the aorta. Methods and Results: Data was collected retrospectively by review medical records from 17 institutions. The data broken down to prior 2002 after further analysis. A total 565 procedures were performed median age 15 years (mean = 18.1 years). Successful reduction in post stent gradient (<20 mm Hg) or increase descending aorta (DAo) ratio >0.8 achieved...
We report a multiinstitutional study on intermediate-term outcome of intravascular stenting for treatment coarctation the aorta using integrated arch imaging (IAI) techniques.Medical records 578 patients from 17 institutions were reviewed. A total 588 procedures performed between May 1989 and Aug 2005. About 27% (160/588) followed up by further IAI their (MRI/CT/repeat cardiac catheterization) after initial stent procedures. Abnormal studies included: presence dissection or aneurysm...
Background— Transcatheter pulmonary valve implantation using the Melody has emerged as an important therapy for treatment of postoperative right ventricular outflow tract dysfunction. Melody-in-bioprosthetic valves (BPV) is currently considered off-label indication. We review combined experience with transcatheter within BPVs from 8 centers in United States and discuss technical aspects Melody-in-BPV procedure. Methods Results— A total 104 patients underwent position at US April 2007 to...
The Harmony transcatheter pulmonary valve (TPV) is the first U.S. Food and Drug Administration–approved device for severe regurgitation (PR) in native or surgically repaired right ventricular outflow tract (RVOT). One-year safety effectiveness of TPV were evaluated patients from Native Outflow Tract Early Feasibility Study, Pivotal Continued Access representing largest cohort to date recipients. Eligible had PR by echocardiography fraction ≥ 30% cardiac magnetic resonance imaging clinical...
Background— The Melody valve is approved for percutaneous pulmonary replacement in dysfunctional right ventricular outflow tracts. function of this when subjected to high-pressure loads humans unknown. aim study was describe the immediate and short-term results valves implanted a environment. Methods Results— Definitions system were established systemic (ie, aortic or mitral position) tract conduit tricuspid annulus) circulations. Implants these environments ascertained from databases 5...
Background: The Melody valve was developed to extend the useful life of previously implanted right ventricular outflow tract (RVOT) conduits or bioprosthetic pulmonary valves, while preserving RV function and reducing lifetime burden surgery for patients with complex congenital heart disease. Methods: Enrollment US Investigational Device Exemption study began in 2007. Extended follow-up completed 2020. primary outcome freedom from transcatheter (TPV) dysfunction (freedom reoperation,...
This study describes 3-year follow-up of 200 infants weighing ≥ 700 grams who underwent transcatheter patent ductus arteriosus (PDA) closure with the Amplatzer Piccolo™ Occluder.Between June 2017 and February 2019, children were enrolled in this U.S. (NCT03055858). PDA closure, survival, device- or procedure-related events evaluated. A total 156 available 182 patients (86%) completed study.The implant success rate was 95.5% (191/200). At 3 years, observed 100% (33/33) patients. Survival >95%...